- Home
- / Oncoceutics
Oncoceutics
Revenue
$5.2 M
FY, 2019
Oncoceutics Summary
Company Summary
- Overview
- Oncoceutics is a drug discovery and development company focused on selective G protein-coupled receptor antagonists for oncology. It offers ONC201, an orally active DRD2 (Dopamine receptor D2) small molecule antagonist that can be used against advanced cancers.
- Type
- Subsidiary
- Status
- Active
- Founded
- 2009
- HQ
- Philadelphia, PA, US | view all locations
- Website
- https://oncoceutics.com
- Cybersecurity rating
Table of Contents
Oncoceutics Financials
Summary Financials
- Revenue (FY, 2019)
- $5.2M
- Net income (FY, 2019)
- ($3.7M)
- Cash (Q3, 2020)
- $5.8M
- EBIT (FY, 2019)
- ($3.9M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2025